- Home
- NBBK vs SLN Comparison
NBBK vs SLN Comparison
Compare NBBK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- SLN
- Stock Information
- Founded
- NBBK 1892
- SLN 1994
- Country
- NBBK United States
- SLN United Kingdom
- Employees
- NBBK N/A
- SLN 116
- Industry
- NBBK
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- SLN Health Care
- Exchange
- NBBK Nasdaq
- SLN Nasdaq
- Market Cap
- NBBK 687.7M
- SLN 273.9M
- IPO Year
- NBBK N/A
- SLN N/A
- Fundamental
- Price
- NBBK $18.76
- SLN $5.52
- Analyst Decision
- NBBK Buy
- SLN Buy
- Analyst Count
- NBBK 1
- SLN 5
- Target Price
- NBBK $22.00
- SLN $32.60
- AVG Volume (30 Days)
- NBBK 471.3K
- SLN 111.1K
- Earning Date
- NBBK 07-23-2025
- SLN 08-14-2025
- Dividend Yield
- NBBK N/A
- SLN N/A
- EPS Growth
- NBBK 421.39
- SLN N/A
- EPS
- NBBK 1.18
- SLN N/A
- Revenue
- NBBK $169,131,000.00
- SLN $27,701,000.00
- Revenue This Year
- NBBK N/A
- SLN N/A
- Revenue Next Year
- NBBK N/A
- SLN N/A
- P/E Ratio
- NBBK $15.93
- SLN N/A
- Revenue Growth
- NBBK 27.71
- SLN N/A
- 52 Week Low
- NBBK $14.84
- SLN $1.97
- 52 Week High
- NBBK $21.05
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- NBBK 75.82
- SLN 51.96
- Support Level
- NBBK $17.70
- SLN $5.33
- Resistance Level
- NBBK $17.31
- SLN $6.05
- Average True Range (ATR)
- NBBK 0.47
- SLN 0.44
- MACD
- NBBK 0.27
- SLN -0.06
- Stochastic Oscillator
- NBBK 90.91
- SLN 38.66
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.